drugset / Trial / NCT02244112
A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this Phase 1 of the study is to evaluate the effect of food on the pharmacokinetics (PK) of oprozomib, the drug-drug interaction of oprozomib with midazolam, and the safety and tolerability of oprozomib in patients with advanced malignancies
Timeline
- Start
- 2014-08
- Primary completion
- 2015-05-15
- Completion
- 2019-07-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Midazolam | Small molecule | 2 mg | Oral |
| Subject | Oprozomib | Small molecule | 270 mg | — |
| Subject | Oprozomib | Small molecule | 300 mg | — |
Indications
No indication recorded.